• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

'Persistent COVID-19 in immunocompromised patients - Israeli society of infectious diseases consensus statement on diagnosis and management': author's response.

作者信息

Meijer Suzy E, Paran Yael, Belkin Ana, Brosh-Nissimov Tal

机构信息

Infectious Disease Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Infectious Disease Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Clin Microbiol Infect. 2024 Sep;30(9):1211-1212. doi: 10.1016/j.cmi.2024.05.022. Epub 2024 May 31.

DOI:10.1016/j.cmi.2024.05.022
PMID:38823451
Abstract
摘要

相似文献

1
'Persistent COVID-19 in immunocompromised patients - Israeli society of infectious diseases consensus statement on diagnosis and management': author's response.《免疫功能低下患者的持续性新冠病毒感染——以色列传染病学会关于诊断和管理的共识声明》：作者回应
Clin Microbiol Infect. 2024 Sep;30(9):1211-1212. doi: 10.1016/j.cmi.2024.05.022. Epub 2024 May 31.
2
Re: Persistent COVID-19 in immunocompromised patients-Israeli Society of Infectious Diseases consensus statement on diagnosis and management by Meijer et al.回复：免疫功能低下患者的持续性新冠病毒感染——梅杰等人撰写的以色列传染病学会关于诊断和管理的共识声明
Clin Microbiol Infect. 2024 Sep;30(9):1209-1210. doi: 10.1016/j.cmi.2024.05.011. Epub 2024 May 21.
3
Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management.免疫功能低下患者的持续性 COVID-19：以色列传染病学会关于诊断和管理的共识声明。
Clin Microbiol Infect. 2024 Aug;30(8):1012-1017. doi: 10.1016/j.cmi.2024.04.009. Epub 2024 Apr 18.
4
Organ Transplantation in the Era of the COVID-19 Global Pandemic.
Isr Med Assoc J. 2021 Mar;23(3):145-146.
5
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients.西班牙传染病与临床微生物学会（SEIMC）移植及其他免疫功能低下宿主感染研究小组（GESITRA-IC）关于实体器官移植受者中SARS-CoV-2感染治疗的共识声明执行摘要。
Transplant Rev (Orlando). 2023 Dec;37(4):100788. doi: 10.1016/j.trre.2023.100788. Epub 2023 Aug 11.
6
Editorial: Therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies.社论：免疫功能低下患者新冠病毒病的治疗管理及其与免疫反应的相互作用：从预防到治疗策略
Front Immunol. 2024 Jul 16;15:1441199. doi: 10.3389/fimmu.2024.1441199. eCollection 2024.
7
Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey.免疫功能低下个体和老年人中第三次 BNT162b2 mRNA COVID-19 疫苗的反应原性-全国性调查。
Clin Immunol. 2021 Nov;232:108860. doi: 10.1016/j.clim.2021.108860. Epub 2021 Sep 24.
8
Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.度普利尤单抗治疗特应性皮炎：SARS-CoV-2感染患者的方案
Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5.
9
COVID-19 in Immunocompromised Patients: A Systematic Review.免疫功能低下患者的 COVID-19：系统评价。
Semin Respir Crit Care Med. 2021 Dec;42(6):839-858. doi: 10.1055/s-0041-1740110. Epub 2021 Dec 16.
10
Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.SARS-CoV-2 在患有非霍奇金淋巴瘤的免疫功能低下患者中的长期进化。
mSphere. 2021 Aug 25;6(4):e0024421. doi: 10.1128/mSphere.00244-21. Epub 2021 Jul 28.

引用本文的文献

1
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.索托维单抗与奈玛特韦/利托那韦或瑞德西韦早期联合使用，在患有轻至中度新冠肺炎的免疫功能低下门诊患者中，持续性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染率较低：一项前瞻性单中心研究。
Ann Med. 2025 Dec;57(1):2439541. doi: 10.1080/07853890.2024.2439541. Epub 2024 Dec 11.
2
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study.替沙格韦单抗-西加韦单抗预防接受抗CD20单克隆抗体治疗的血液病患者发生重症新型冠状病毒肺炎：一项国际多中心研究
Infect Dis Ther. 2025 Jan;14(1):167-180. doi: 10.1007/s40121-024-01089-9. Epub 2024 Dec 9.